Group 1 - The company, Jiangsu Jibeier Pharmaceutical Co., Ltd., has received the approval notice for the listing application of the chemical raw material drug Gatifloxacin from the National Medical Products Administration [1][2] - Gatifloxacin is a broad-spectrum antibacterial drug effective against various bacteria, including Gram-positive and Gram-negative bacteria, and is the main raw material for the company's Gatifloxacin eye drops [2] - The approval is valid until October 21, 2030, and the company is required to continue accumulating research data on nitrosamine impurities and improve control strategies as necessary [2] Group 2 - The approved Gatifloxacin raw material is primarily used to meet the production needs of the company's Gatifloxacin eye drops, and it is not expected to have a significant impact on the company's recent operations [3]

Core Viewpoint - The company, Jibeier, has received approval from the National Medical Products Administration for its chemical raw material drug listing application [2] Group 1 - The approval notification was officially issued on the evening of October 23 [2]

证券代码：688566 证券简称：吉贝尔 公告编号：2025-047 江苏吉贝尔药业股份有限公司 自愿披露关于收到化学原料药上市申请批准 通知书的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，江苏吉贝尔药业股份有限公司（以下简称"公司"）收到国家药品监 督管理局签发的《化学原料药上市申请批准通知书》，现将相关情况公告如下： 一、基本信息 1、登记号：Y20240000024 2、化学原料药名称：通用名称：加替沙星；英文名/拉丁名：Gatifloxacin 3、化学原料药注册标准编号：YBY70952025 4、包装规格：3kg/桶 5、申请事项：境内生产化学原料药上市申请 6、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执 行。请继续积累亚硝胺杂质的研究数据，必要时完善控制策略。 7、生产企业：名称：江苏吉贝尔药业股份有限公司；地址：江苏省镇江市 高新技术产业开发园区 江苏吉贝尔药业股份有限公司董事会 2025 年 10 月 ...

Core Viewpoint - The company, Jibeier (688566.SH), has received the approval notice for the marketing application of its chemical raw material, gatifloxacin, from the National Medical Products Administration, indicating a significant advancement in its product pipeline [1]. Group 1: Product Information - Gatifloxacin is a quinolone antibiotic effective against various bacteria, including Gram-positive and Gram-negative bacteria, as well as Chlamydia trachomatis [1]. - The product gatifloxacin eye drops, which utilize gatifloxacin as the main raw material, are primarily used for treating acute bacterial conjunctivitis caused by sensitive bacteria [1]. - The antibacterial action of gatifloxacin is achieved by inhibiting bacterial DNA gyrase and topoisomerase IV, thereby blocking the processes of DNA replication, transcription, and repair [1].

Core Viewpoint - The company, Jibeier (688566), has received approval from the National Medical Products Administration for its chemical raw material, gatifloxacin, which is the main ingredient in its gatifloxacin eye drops used for treating acute bacterial conjunctivitis caused by sensitive bacteria [1] Group 1 - The approval notification is specifically for the chemical raw material drug application [1] - Gatifloxacin eye drops are primarily indicated for acute bacterial conjunctivitis [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 江苏吉贝尔药业股份有限公司（以下简称"公司"）董事会于 2025 年 10 月 22 日收到公司董事张春先生的辞职报告，因工作调整，张春先生申请辞去公司 董事职务，辞任后继续在公司担任设备总监职务。同日，公司召开职工代表大会， 经与会职工代表一致同意，选举张春先生担任公司第四届董事会职工代表董事， 任期自本次职工代表大会选举通过之日起至公司第四届董事会届满之日止。 一、董事离任情况 | 姓名 | 离任职务 | 离任时间 | | 原定任期 | | 离任原因 | 是否继续 在上市公 | 具体 | 是否存在 未履行完 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 到期日 | | | 司及其控 股子公司 | 职务 | 毕的公开 承诺 | | | | | | | | | 任职 | | | | 张春 | 董事 | 2025 年 | 10 | 2026 年 9 | | 工作 ...

Core Points - The company announced that Mr. Zhang Chun submitted his resignation as a director due to work adjustments, but will continue to serve as the Equipment Director [1] - A workers' representative meeting was held on the same day, where Mr. Zhang Chun was elected as a worker representative director for the fourth board of directors, with a term lasting until the board's term ends [1] - Mr. Zhang Chun's resignation will take effect upon the delivery of his resignation report to the board, and his departure will not reduce the number of board members below the legal requirement [1]

Group 1 - The core viewpoint of the news is that Jibeier's stock has shown significant fluctuations, with a year-to-date increase of 55.07% but a recent decline over the past five and twenty trading days [1] - As of October 16, Jibeier's stock price was 33.93 CNY per share, with a market capitalization of 6.767 billion CNY [1] - The company has experienced a net outflow of main funds amounting to 2.3898 million CNY, while large orders showed a mixed trend with buying at 5.0187 million CNY and selling at 8.2008 million CNY [1] Group 2 - For the first half of 2025, Jibeier reported a revenue of 455 million CNY, reflecting a year-on-year growth of 4.90%, and a net profit attributable to shareholders of 149 million CNY, which is a 22.38% increase compared to the previous year [2] - The company has distributed a total of 476 million CNY in dividends since its A-share listing, with 296 million CNY distributed over the last three years [3] Group 3 - Jibeier's main business includes drug research, production, and sales, with the primary revenue sources being Likujun tablets (72.72%), Niquinlor tablets (14.20%), and Yupingfeng capsules (4.88%) [1] - The company is categorized under the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and preparations, and is involved in innovative drugs and cancer treatment [1]

Core Viewpoint - The arbitration case involving Jiangsu Jibeier Pharmaceutical Co., Ltd. and Shenzhen Huada Ocean Technology Co., Ltd. has reached a significant stage, with the Shanghai First Intermediate People's Court rejecting Huada Ocean's application to overturn the arbitration ruling [2][3][5] Group 1: Arbitration Case Overview - The arbitration was initiated by Jiangsu Jibeier Pharmaceutical against Huada Ocean regarding a share repurchase dispute related to Shenzhen Huahong Ocean Biological Pharmaceutical Co., Ltd. [2] - The Shanghai International Economic and Trade Arbitration Commission issued a ruling (No. 3816) on this matter, which is detailed in the company's announcements on the Shanghai Stock Exchange [2] Group 2: Recent Developments - Huada Ocean has filed an application to the Shanghai First Intermediate People's Court to annul the arbitration ruling, but the court has recently issued a civil ruling rejecting this application [2][3][5] - The ruling from the arbitration commission is considered final, and its impact on the company's financial performance will depend on the actual execution of the ruling [3][5]

Core Viewpoint - The stock of Jibeier has shown significant fluctuations, with a year-to-date increase of 52.10%, but recent declines in the short term indicate potential volatility in investor sentiment [1][2]. Group 1: Stock Performance - On October 15, Jibeier's stock rose by 2.02%, reaching a price of 33.28 CNY per share, with a trading volume of 18.48 million CNY and a turnover rate of 0.28% [1]. - The total market capitalization of Jibeier is 6.637 billion CNY [1]. - Year-to-date, the stock has increased by 52.10%, but it has decreased by 6.75% over the last five trading days and 8.42% over the last twenty days [1]. Group 2: Financial Performance - For the first half of 2025, Jibeier reported a revenue of 455 million CNY, representing a year-on-year growth of 4.90%, and a net profit attributable to shareholders of 149 million CNY, which is a 22.38% increase compared to the previous year [2]. - Since its A-share listing, Jibeier has distributed a total of 476 million CNY in dividends, with 296 million CNY distributed over the last three years [3]. Group 3: Business Overview - Jibeier, established on November 13, 2001, and listed on May 18, 2020, is primarily engaged in the research, production, and sales of pharmaceuticals [1]. - The main revenue sources for Jibeier include Likujun tablets (72.72%), Niqurolol tablets (14.20%), Yupingfeng capsules (4.88%), and other products [1]. - Jibeier operates within the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and formulations, and is involved in innovative drugs and cancer treatment [1].